Sparta Systems Promotes William B. Gerraughty, Jr. to Chief Operating Officer
Sparta Systems, Inc., has promoted William B. Gerraughty, Jr., to the role of chief operating officer (COO). Gerraughty, who currently serves as chief financial officer (CFO), will assume the responsibility of overseeing the company’s day-to-day operations, provide strategic planning and resource allocation, and advise the CEO and management team on key planning issues and important business decisions. Gerraughty will continue to serve as CFO and manage the company’s legal and human resource departments.
Before Sparta Systems, Gerraughty served as CFO at two publicly traded companies, NMS Communications and Infinium Software. He also held a number of executive positions, including president, COO and CFO at Intellution, a software company serving the industrial automation markets. Gerraughty began his career at Coopers and Lybrand.
“William Gerraughty’s success in ensuring the financial health of Sparta Systems makes him a natural choice to oversee the company’s daily operation as we head into 2010,” said James E. McGowan, CEO, Sparta Systems. “I’m confident that with his unparalleled record of accomplishment and complete knowledge of the company’s inner workings, his promotion to COO will help position Sparta for continued growth in the coming year and beyond.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
